Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @cnsternberg
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @cnsternberg
-
Congratulations to all for this important endeavor!https://twitter.com/EUplatinum/status/1222113962222858240 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congratulations and well deserved!!https://twitter.com/neerajaiims/status/1222412843040952321 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Precion delivery of cancer care is the next step!https://twitter.com/ASCO/status/1220806603273715712 …
0:59Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
How cool is this?!


Deterministic Barcoding in Tissue for spatial omics sequencing (DBiT-seq). mRNA, Protein and more barcoded using parallel microfluidic channels on FFPE enabling the construction of a high-spatial-resolution multi-omics atlas by NGS sequencing.https://twitter.com/RongFan8/status/1179186817234604032 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
Addresses important ?’s. Don’t give higher dose or more than 6 cycles as single agent. Still wonder about retreatmenthttps://twitter.com/EngIPM/status/1217470732684447744 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
Announcing the new issue of our
@BladderCaJrnl! Issue 5:4 has the very latest review and research articles#newissue#openlyavailable Read all content at https://content.iospress.com/journals/bladder-cancer/5/4 …@BladderCancerUSpic.twitter.com/iQl0n44pj5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congratulations!!!! Corahttps://twitter.com/jsoriamd/status/1213198913659973632 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
Recommended reading for
#Christmas break: How I Treat Side Effects of Immunotherapy Special Issue ESMO - European Society for Medical Oncology The Daily Tweet#TDThttps://esmoopen.bmj.com/content/4/Suppl_4 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
#WatchNow Continuing the momentum with patient advocacy@EHeath4100@karmanoscancer and@CaPsurvivorship@NUFeinbergMed discuss the importance of patient advocacy, education, and the impact advocacy has on a cancer patients' journey on UroToday > http://bit.ly/327FvX5 pic.twitter.com/fJMzwxlhaO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
Video: "How the Cancer Genome Atlas has impacted
#bladdercancer management," with Dr Seth Lerner https://www.urologytimes.com/suo-annual-meeting/how-cancer-genome-atlas-has-impacted-bladder-ca-management …#urologypic.twitter.com/W6OPKduuzN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
There’s No Winter Break From ‘Publish or Perish’ via
@nytimes -new data showing a substantial proportion of manuscript submissions & journal reviews done over the holidays
https://www.nytimes.com/2019/12/18/science/scientists-holiday-work.html …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
Huge news for
#bladdercancer with new agent (EV) approved! More to come! Good to look ORR & outcomes with EV in pts with FGFR alterations! Field moving forward@BladderCancerUS@IBCG_BladderCA@IBCN1997@bladderau@ArjunBalarMD@MattGalsky@FDAOncology@ERPlimackMD@apolo_andreapic.twitter.com/sAPAsB3baG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
I am proud to say that Enfortumab vedotin was approved by the FDA today for advanced bladder cancer. A heartfelt thanks to all the patients and families who volunteered for the clinical trials. And a special thanks to our research staff and nurses who worked tirelessly.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
Enfortumab Vedotin is clearly very active in bladder cancer with over 40% RR in refractory disease. The randomised 301 trial will determine the degree of benifit. Also, EV with pembro could replace front line chemo in view of the >70% RR. Patient will want this too I suspect.pic.twitter.com/SDj0qe8vZ3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
Congrats Betsy
@ERPlimackMD on your election to@ASCO Board of Directors !! Richly deserved!https://twitter.com/ASCO/status/1206956467322052610 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
FDA Approves Enfortumab Vedotin for Urothelial Cancer https://www.onclive.com/web-exclusives/fda-approves-enfortumab-vedotin-for-urothelial-cancer?utm_medium=email … via
@oncliveHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
@tompowles1 welcome to Twitter! We are happy to have in our GU community@TiansterZhang@DrChoueiri@montypal@PGrivasMDPhD@ERPlimackMD@sonpavde@drenriquegrande@AndreaNecchi@FaltasLab@cnsternberg@ScotNiglio@MattGalsky@PrimoLaraMD@DrDarrenFeldman@DiogoAssed@neerajaiimsHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
Great interview with
@EngIPM Clinical Director Cora N. Sternberg, M.D. (@cnsternberg).#PrecisionMedicinehttps://twitter.com/cornellGUcancer/status/1201980702973190144 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Cora Sternberg proslijedio/la je Tweet
“This trial, absolutely, is paradigm-changing,”
@cnsternberg tells@urotoday. Watch as she discusses the CARD study of cabazitaxel vs abiraterone or enzalutamide in metastatic#prostatecancer. https://bit.ly/37EQHO6@urotoday#pcsmpic.twitter.com/Ey9ST8E0o6
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A great talk by Seth Lerner today
@EngIPMhttps://twitter.com/FaltasLab/status/1201882718902145031 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

precision delivery of cancer care